June 27, 2022

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Re: InMed Pharmaceuticals Inc. Registration Statement on Form S-1, filed on June 21, 2022 As amended by Amendment No. 1 to the Registration Statement on Form S-1, filed on June 24, 2022 File No. 333-265731

Ladies and Gentlemen:

On behalf of InMed Pharmaceuticals Inc., a British Columbia corporation (the “Company”), the undersigned hereby respectfully submits its request for acceleration of effectiveness. Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned hereby requests that the effective date of the above referenced Registration Statement on Form S-1, as amended (the “Registration Statement”), be accelerated so that the same will become effective at 4:00 p.m., Washington, D.C. time, on Wednesday, June 29, 2022, or as soon as practicable thereafter.

Please notify Brian P. Fenske of Norton Rose Fulbright US LLP, counsel to the Company, at (713) 651-5557 or at brian.fenske@nortonrosefulbright.com, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.

Very truly yours,
InMed Pharmaceuticals Inc.
By:	/s/ Eric A. Adams
Name:	Eric A. Adams
Title:	President and Chief Executive Officer